DK0841928T3 - Sustained release-formulering af d-threo-methylphenidat - Google Patents

Sustained release-formulering af d-threo-methylphenidat

Info

Publication number
DK0841928T3
DK0841928T3 DK96924083T DK96924083T DK0841928T3 DK 0841928 T3 DK0841928 T3 DK 0841928T3 DK 96924083 T DK96924083 T DK 96924083T DK 96924083 T DK96924083 T DK 96924083T DK 0841928 T3 DK0841928 T3 DK 0841928T3
Authority
DK
Denmark
Prior art keywords
threo
methylphenidate
release formulation
sustained release
sustained
Prior art date
Application number
DK96924083T
Other languages
English (en)
Inventor
Helen Frances Chiroscien Baker
Julian Clive Chiroscie Gilbert
Original Assignee
Medeva Europ Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medeva Europ Ltd filed Critical Medeva Europ Ltd
Application granted granted Critical
Publication of DK0841928T3 publication Critical patent/DK0841928T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
DK96924083T 1995-07-14 1996-07-15 Sustained release-formulering af d-threo-methylphenidat DK0841928T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9514451.5A GB9514451D0 (en) 1995-07-14 1995-07-14 Sustained-release formulation
PCT/GB1996/001690 WO1997003673A1 (en) 1995-07-14 1996-07-15 Sustained-release formulation of d-threo-methylphenidate

Publications (1)

Publication Number Publication Date
DK0841928T3 true DK0841928T3 (da) 2003-01-27

Family

ID=10777685

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96924083T DK0841928T3 (da) 1995-07-14 1996-07-15 Sustained release-formulering af d-threo-methylphenidat

Country Status (17)

Country Link
US (1) US5874090A (da)
EP (1) EP0841928B1 (da)
JP (1) JPH11509228A (da)
KR (1) KR100481416B1 (da)
AT (1) ATE224715T1 (da)
AU (1) AU702371B2 (da)
CA (1) CA2223643C (da)
CZ (1) CZ285956B6 (da)
DE (1) DE69623970T2 (da)
DK (1) DK0841928T3 (da)
ES (1) ES2186790T3 (da)
GB (1) GB9514451D0 (da)
HU (1) HU224314B1 (da)
MX (1) MX9800394A (da)
PT (1) PT841928E (da)
SK (1) SK281569B6 (da)
WO (1) WO1997003673A1 (da)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
AU708873B2 (en) 1995-07-14 1999-08-12 Medeva Europe Limited Composition comprising d-threo-methylphenidate and another drug
US7081238B2 (en) * 1995-11-03 2006-07-25 The President And Fellows Of Harvard College Methods for diagnosing and monitoring treatment ADHD by assessing the dopamine transporter level
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US6355656B1 (en) * 1995-12-04 2002-03-12 Celgene Corporation Phenidate drug formulations having diminished abuse potential
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US5733756A (en) * 1996-01-05 1998-03-31 Celgene Corporation Lactams and processes for stereoselective enrichment of lactams, amides, and esters
US5908850A (en) * 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
US6919373B1 (en) * 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
US6962997B1 (en) * 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
US20020102291A1 (en) * 1997-12-15 2002-08-01 Noven Pharmaceuticals, Inc. Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
US20010055613A1 (en) * 1998-10-21 2001-12-27 Beth A. Burnside Oral pulsed dose drug delivery system
US20060240105A1 (en) * 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
WO2000025752A1 (en) * 1998-11-02 2000-05-11 Church, Marla, J. Multiparticulate modified release composition
US20090149479A1 (en) * 1998-11-02 2009-06-11 Elan Pharma International Limited Dosing regimen
US6673367B1 (en) * 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
US7083808B2 (en) 1998-12-17 2006-08-01 Euro-Celtique S.A. Controlled/modified release oral methylphenidate formulations
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6127385A (en) * 1999-03-04 2000-10-03 Pharmaquest Limited Method of treating depression using l-threo-methylphenidate
US6395752B1 (en) * 1999-03-04 2002-05-28 Pharmaquest Limited Method of treating depression using 1-threo-methylphenidate
US6217904B1 (en) 1999-04-06 2001-04-17 Pharmaquest Ltd. Pharmaceutical dosage form for pulsatile delivery of d-threo-methylphenidate and a second CNS stimulant
US20030170181A1 (en) * 1999-04-06 2003-09-11 Midha Kamal K. Method for preventing abuse of methylphenidate
US7553478B2 (en) * 1999-05-12 2009-06-30 President And Fellows Of Harvard College Methods for diagnosing and monitoring treatment ADHD by assessing the dopamine transporter level
GB9913458D0 (en) * 1999-06-09 1999-08-11 Medeva Europ Ltd The therapeutic use of d-threo-methylphenidate
US20100143248A1 (en) * 1999-06-28 2010-06-10 President And Fellows Of Harvard College Methods for diagnosing and monitoring treatment of adhd by assessing the dopamine transporter level
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
BRPI0015284B8 (pt) 1999-10-29 2021-05-25 Euro Celtique S/A formulações de hidrocodona de liberação controlada
JP3856283B2 (ja) * 2000-02-14 2006-12-13 シャープ株式会社 固体撮像装置および撮像装置の駆動方法
US6221883B1 (en) * 2000-04-12 2001-04-24 Ross Baldessarini Method of dopamine inhibition using l-threo-methylphenidate
EP1163907B1 (en) * 2000-06-17 2006-04-12 Pharmaquest Limited Use of l-threo-methylphenidate for the manufacture of a medicament for the treatment of depression
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
KR101045144B1 (ko) 2000-10-30 2011-06-30 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US20020187192A1 (en) * 2001-04-30 2002-12-12 Yatindra Joshi Pharmaceutical composition which reduces or eliminates drug abuse potential
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030049272A1 (en) * 2001-08-30 2003-03-13 Yatindra Joshi Pharmaceutical composition which produces irritation
US6638533B2 (en) 2002-01-03 2003-10-28 George Krsek Pulse dosage formulations of methylphenidate and method to prepare same
US20050232995A1 (en) * 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US20050208132A1 (en) * 2002-07-29 2005-09-22 Gayatri Sathyan Methods and dosage forms for reducing side effects of benzisozazole derivatives
US20080220074A1 (en) * 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
US7988993B2 (en) * 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
US20050239830A1 (en) * 2004-04-26 2005-10-27 Vikram Khetani Methods of diminishing co-abuse potential
WO2006063078A2 (en) * 2004-12-08 2006-06-15 Elan Corporation, Plc Topiramate pharmaceuticals composition
CA2591247A1 (en) * 2004-12-09 2006-06-15 Celgene Corporation Treatment of patients suffering from a disease having a family history or diagnosis of tics or tourette's syndrome with d-threo methylphenidate
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
EA200702221A1 (ru) * 2005-04-12 2008-04-28 Элан Фарма Интернэшнл Лимитед Композиции с контролируемым высвобождением для лечения бактериальной инфекции, содержащие цефалоспорин
WO2007037790A2 (en) * 2005-06-08 2007-04-05 Elan Corporation, Plc Modified release famciclovir compositions
EP2428205B1 (en) 2006-03-16 2012-10-03 Tris Pharma, Inc. Modified release formulations containing drug-ion exchange resin complexes
US8846100B2 (en) 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
US8709477B2 (en) * 2009-08-13 2014-04-29 Kremers Urban Pharmaceuticals, Inc` Pharmaceutical dosage form
US8623409B1 (en) 2010-10-20 2014-01-07 Tris Pharma Inc. Clonidine formulation
US8287903B2 (en) 2011-02-15 2012-10-16 Tris Pharma Inc Orally effective methylphenidate extended release powder and aqueous suspension product
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
EP3272342B1 (en) 2011-03-23 2021-05-26 Ironshore Pharmaceuticals & Development, Inc. Methods and compositions for treatment of attention deficit disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
CA2880456A1 (en) 2012-08-15 2014-02-20 Tris Pharma, Inc. Methylphenidate extended release chewable tablet
CA2936741C (en) 2014-10-31 2018-11-06 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
KR102174787B1 (ko) 2018-11-14 2020-11-05 호서대학교 산학협력단 재사용이 가능한 다용도 로드 및 이를 갖는 약물 투여기
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US11918689B1 (en) 2020-07-28 2024-03-05 Tris Pharma Inc Liquid clonidine extended release composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2507631A (en) * 1944-01-19 1950-05-16 Ciba Pharm Prod Inc Pyridine and piperidine compounds and process of making same
US2838519A (en) * 1953-12-23 1958-06-10 Ciba Pharm Prod Inc Process for the conversion of stereoisomers
US2957880A (en) * 1953-12-23 1960-10-25 Ciba Pharm Prod Inc Process for the conversion of stereoisomers
US4192827A (en) * 1974-06-27 1980-03-11 Ciba-Geigy Corporation Water-insoluble hydrophilic copolymers
US5583140A (en) * 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders

Also Published As

Publication number Publication date
MX9800394A (es) 1998-09-30
SK281569B6 (sk) 2001-05-10
ATE224715T1 (de) 2002-10-15
AU702371B2 (en) 1999-02-18
KR100481416B1 (ko) 2005-07-29
AU6466196A (en) 1997-02-18
CA2223643A1 (en) 1997-02-06
PT841928E (pt) 2002-12-31
ES2186790T3 (es) 2003-05-16
DE69623970D1 (de) 2002-10-31
HUP9802252A2 (hu) 1999-01-28
EP0841928A1 (en) 1998-05-20
US5874090A (en) 1999-02-23
CZ285956B6 (cs) 1999-12-15
CZ9298A3 (cs) 1998-06-17
EP0841928B1 (en) 2002-09-25
SK2998A3 (en) 1998-07-08
HUP9802252A3 (en) 1999-04-28
DE69623970T2 (de) 2003-06-05
HU224314B1 (hu) 2005-07-28
CA2223643C (en) 2003-12-23
JPH11509228A (ja) 1999-08-17
KR19990028984A (ko) 1999-04-15
WO1997003673A1 (en) 1997-02-06
GB9514451D0 (en) 1995-09-13

Similar Documents

Publication Publication Date Title
DK0841928T3 (da) Sustained release-formulering af d-threo-methylphenidat
DK0770615T3 (da) Fremgangsmåde til fremstilling af dihalogenazolopyrimidiner
DK0769947T3 (da) Indolinonforbindelser til behandling af sygdom
DK1007092T3 (da) En fremgangsmåde til inhibering af komplementaktivering via det alternative forlöb
PT1114817E (pt) Compostos benzilamino piperidina substituidos
TR199800011T1 (xx) Benzo$g] kuinolin t�revleri
TR199501132A2 (tr) Nörokinin karsitlari (antagonistleri).
DK0830337T3 (da) Fremgangsmåde til hydrogenering af iminer
DE69831409D1 (de) Chalcon-derivate mit antiproliferativer aktivität
DK0768310T3 (da) Fremgangsmåde til fremstilling af imidazo-benzodiazepin-derivater
DK0877738T3 (da) Fremgangsmåde til fremstilling af phenylimidazolidinderivater
FI901987A0 (fi) Anordning foer blaosformning av en ihaolig kropp.
DE69230224D1 (de) Potenzierung von nmda-antagonisten
DK0946514T3 (da) Fremgangsmåde til fremstilling af n-substituerede 3-hydroxypyrazoler
DK0815092T3 (da) Fremgangsmåde til fremstilling af 1,2-benzisothiazolin-3-oner
DE69736180D1 (de) Behandlung von manischen erkrankungen
DK0735043T3 (da) Fremgangsmåde til fremstilling af 2-substitueret 3,3-difluorfuran
DK0721929T3 (da) Fremgangsmåde til fremstilling af hydroxyalkoxybenzophenoner
ID21920A (id) 4-6-fluoro-(1h)-indol-3-il-1,2,3,6-tetrahidropirin tersubstitusi untuk pengobatan gangguan cns
KR970701687A (ko) 레조르시놀로부터의 4, 6-디니트로레조르시놀의 일단계 제조방법 (One-step preparation of 4,6-dinitroresorcinol from resorcinol)
FI973235A (fi) Menetelmä IL-6:n vaikutusten inhiboimiseksi
DE59809538D1 (de) Verfahren zur Herstellung von 1,2,3,6-Tetrahydro-2,2,6,6-tetramethylpyridin
DK0729971T3 (da) Fremgangsmåde til fremstilling af ivermectin
DK0783491T3 (da) Fremgangsmåde til fremstilling af 3,3,5-trichlorglutarimid
NO891681D0 (no) Fremgangsmaate for syntese av c5+ hydrokarboner.